Venlafaxine (Effexor) and Desvenlafaxine (Pristiq) – Mechanism of Action | Differences | Psychopharmacology | Clinical Application
Venlafaxine (EFFEXOR) is a serotonin and noradrenaline reuptake inhibitor (SNRI) that is indicated for major depressive disorder (MDD), generalised anxiety disorder, social anxiety disorder, and panic disorder with or without agoraphobia.
Desvenlafaxine (PRISTIQ) is a synthetic succinate version of venlafaxine’s major active metabolite, although its approval is limited to MDD.
Venlafaxine was the first SNRI to be approved by the US FDA (in 1993), and its novel phenethylamine bicyclic structure is structurally unrelated to other antidepressants. [Warneck et al. 2008]
DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007 May;68(5):677-88.], [Laoutidis, Z. G., & Kioulos, K. T. (2015). Desvenlafaxine for the acute treatment of depression: a systematic review and meta-analysis. Pharmacopsychiatry, 25(06), 187-199].
Hoskins, M. D., Bridges, J., Sinnerton, R., Nakamura, A., Underwood, J. F., Slater, A., … & Bisson, J. I. (2021). Pharmacological therapy for post-traumatic stress disorder: A systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches. European Journal of Psychotraumatology, 12(1), 1802920.